Evaluating Post-discharge Thromboembolic Events in Patients With COVID-19
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 12 No. 3 (2022),
,
Page 36851
https://doi.org/10.32598/ijmtfm.vi.36851
Abstract
Background: COVID-19 is associated with a high rate of thromboembolic events in hospitalized patients, but it is unclear whether this risk remains high after discharge. This study aimed to evaluate the association of underlying factors with post-discharge thrombolytic events in COVID-19 patients and the association of thrombolytic events with subsequent mortality and ischemic heart disease.
Methods: In this study, eligible patients with COVID-19 who were admitted to the respiratory ward of Loghman Hakim Hospital, Tehran, Iran, followed up for about 3 months after discharge to record any thromboembolic events. Patients who reported post-discharge thromboembolic events were confirmed based on their diagnostic tests. The Chi-square test was used to evaluate the association between thromboembolic events and qualitative parameters, and an independent t-test was used to evaluate their association with quantitative parameters. Logistic regression analysis was performed to assess the association between independent variables and the composite outcome.
Results: Thromboembolic events were diagnosed in 35 patients (5.04%), including Myocardial Infarction (MI) in 17 patients (2.44%), venous thromboembolism in 10 patients (1.44%), and ischemic stroke in 8 patients (1.15%). None of the 26 patients who received thromboprophylaxis had thromboembolic events. During follow-up, 22 patients (3.17%) died, of whom, 10 patients (43.47%) had thromboembolic events. Thromboembolic events were not associated with sedentary life and oxygen (O2) dependency after discharge (P value of 0.40 and 0.098, respectively). Regression analyses showed that thromboembolic events were significantly associated with ischemic heart disease and mortality (P=0.007 and P<0.001, respectively).
Conclusion: Our findings support a high rate of post-hospitalization thromboembolic events in COVID-19 patients; however, it needs more large-scale trials.
- Thromboembolic events
- COVID-19
- Post-discharge
- Extended thromboprophylaxis
How to Cite
References
-Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149(38‐44):13.
- Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019;9(1):19. 14.
-Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019; 181:77‐83
-Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001; 86:1327‐1330
-Cattaneo M, Bertinato EM, Birocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID‐19? is the recommendation to use high‐dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120(8):1230–1232.
- Jin S, Jin Y, Xu B, Hong J, Yang X. Prevalence and impact of coagulation dysfunction in COVID-19 in China: a meta-analysis. Thromb Haemost. 2020;120(11):1524–35.
-Savas Ozsu, Ersin Gunay, Stavros V. Konstantinides A review of venous thromboembolism in COVID-19: A clinical perspective The Clinical Respiratory Journal 2021; 15(5):506-512
-Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, Zhou X, Jiang W, Zhao YQ, Zhang SY, Li TS (2020) Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Chin J Hematol 41: E006.
-Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. 2020; N Engl J Med 382(17): e38.
- Farid Rashidi et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study Thromb Res. 2021 Feb; 198: 135–138.
-Dimitrios Giannis et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry Blood. 2021. 20;137(20)
- Paul Fontelo , Mrigendra M Bastola , Zhaonian Zheng , Seo Hyon Baik- A review of thromboembolic events in hospitalized COVID-19 patients. Thromb J. 2021 Jun 29;19(1):47.
-Harish Eswaran Et al. Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors . Res Pract Thromb Haemost. 2021 Feb 8;5(2):292-295
- Abstract Viewed: 60 times
- pdf Downloaded: 18 times